AbbVie Inc. ($ABBV) Stock Forecast: Down 8.6% Today

What is AbbVie Inc.?

AbbVie (ABBV:NYSE) is a biopharmaceutical company recognized for its flagship drug Humira and a variety of immunology and neuroscience products. The stock exhibited a downward trend today despite announcing robust financial results for Q4 2025.

Why is AbbVie Inc. going down?

ABBV stock is down 8.6% on Feb 4, 2026 14:37

• AbbVie surpassed analyst estimates with its financial performance in Q4 2025, including strong revenue figures and a notable showing by Humira.
• Despite the optimistic earnings report and an increased profit forecast for 2026, the stock saw a minor decline, potentially influenced by investors taking profits following recent positive developments.
• Market response indicates that notwithstanding the company's positive outlook and solid performance, investors may have held elevated expectations or concerns regarding the future earnings impact of Humira's patent expiration.
• The slight drop in the stock price might also be linked to general market conditions or specific challenges within the pharmaceutical sector affecting investor sentiment.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

AbbVie stock slips despite Q4 beat (ABBV:NYSE)

AbbVie reported better-than-expected financials for Q4 2025, with revenue of $16.6 billion, a 10% year-over-year growth, surpassing analyst estimates. This performance was largely driven by Humira, which exceeded Street forecasts, despite a mixed performance from its newer immunology drugs, Rinvoq and Skyrizi. Despite these positive results, AbbVie's stock experienced a slight dip.

https://seekingalpha.com/news/4547001-abbvie-stock-slips-despite-q4-beat

AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss

AbbVie Inc. (NYSE:ABBV) reported a mixed Q4 2025 with revenue of $16.62 billion slightly missing analyst estimates, but non-GAAP EPS of $2.71 narrowly beating expectations. Despite an initial pre-market dip, the company raised its 2026 profit forecast, driven by a rebound in its aesthetics business. This bullish guidance suggests confidence in strategic efforts amidst the ongoing transition post-Humira's patent cliff.

https://www.chartmill.com/news/ABBV/Chartmill-41090-AbbVie-Inc-NYSEABBV-Raises-2026-Outlook-Despite-Q4-Revenue-Miss

AbbVie's (NYSE:ABBV) Q4 CY2025: Beats On Revenue

AbbVie (NYSE:ABBV) reported Q4 CY2025 results that surpassed revenue and non-GAAP profit expectations, with sales up 10% year-on-year to $16.62 billion. The biopharmaceutical company also provided a positive adjusted EPS guidance for the upcoming financial year 2026, beating analyst estimates. Despite strong earnings, shares traded down slightly immediately following the results.

https://finviz.com/news/299131/abbvies-nyse-abbv-q4-cy2025-beats-on-revenue

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie reported better-than-expected earnings for the fourth quarter and provided strong guidance for 2026, surpassing consensus estimates. Despite these positive results, the drugmaker's stock experienced a decline on Wednesday. The article notes that the good news did not prevent the stock from falling.

https://www.barrons.com/articles/abbvie-earnings-stock-price-5f0b25c7?gaa_at=eafs&gaa_n=AWEtsqct6K0TLAxyFG3bwwjMvw-3VvVTmV8jcZ1PljbVsxVbMIdSGNEmj87W&gaa_ts=69834c0f&gaa_sig=EdZjfgKahewn6-3wxipCsiaIdlkiQLJeG2VjptuqkQJAV4O6EVflB793ECzZnHkma2YH6Hr6OBr0g6-8RQD01g%3D%3D

AbbVie beats Q4 expectations, shares dip

AbbVie Inc. exceeded analyst expectations for both Q4 earnings and revenue, driven by strong performance in its immunology and neuroscience portfolios. Despite these positive results, the pharmaceutical giant's shares dipped 2.5% in premarket trading. The company also issued full-year 2026 adjusted earnings guidance above analyst consensus.

https://www.investing.com/news/earnings/abbvie-beats-q4-expectations-shares-dip-4484632

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Up 6.1% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.0% Today

AbbVie Inc. Price History

28.09.2025 - ABBV Stock was up 0.0%

• AbbVie's recent market upturn is linked to positive market expectations for its upcoming Q3 earnings, with a particular focus on the growth of Skyrizi and Rinvoq.
• Market sentiment remains optimistic about AbbVie's future prospects despite analyst predictions of an earnings decrease, driven by the success of its leading drugs.
• Although the stock saw a slight decline compared to the overall market recently, the company has demonstrated significant growth of over 30% in the last six months, led by robust sales and product efficacy.
• Investors are considering AbbVie as a favorable investment option, undeterred by some doubts from financial analysts, given the company's strong track record and growth potential in key therapeutic areas.

12.04.2025 - ABBV Stock was up 5.2%

• Uncommon options behavior indicated a positive outlook on AbbVie, attracting investor attention and contributing to the bullish trend.
• Reports of substantial AbbVie stock acquisitions by legislators may have boosted confidence in the company's future, driving up buying interest.
• Despite ongoing legal challenges, the positive publicity surrounding influential individuals investing in AbbVie likely overshadowed any potential negativity, pushing the stock price up.
• The optimistic options activity and significant stock acquisitions by government officials probably fostered a favorable outlook on AbbVie, prompting the bullish movement in the market.

05.00.2026 - ABBV Stock was down 2.6%

• Today's bearish movement in AbbVie's stock price can be attributed to several factors:
• Despite strong Q3 earnings and dividend increases, the reduction in holdings by institutional investors like Railway Pension Investments Ltd and Commonwealth Equity Services LLC may have signaled concerns about the company's future growth prospects.
• The $100 million upfront investment in the trispecific lung cancer drug ZG006, while positioning AbbVie to challenge competitors like Amgen, might have raised investor worries about the high costs and risks associated with drug development.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could have led to profit-taking by some traders who may have been expecting more significant announcements or guidance from the management.
• The overall market sentiment towards pharmaceutical companies and healthcare stocks today might have also played a role in the bearish movement of AbbVie's stock, as investors may be rotating their portfolios based on sector performance and economic outlook.

04.01.2026 - ABBV Stock was down 8.6%

• AbbVie surpassed analyst estimates with its financial performance in Q4 2025, including strong revenue figures and a notable showing by Humira.
• Despite the optimistic earnings report and an increased profit forecast for 2026, the stock saw a minor decline, potentially influenced by investors taking profits following recent positive developments.
• Market response indicates that notwithstanding the company's positive outlook and solid performance, investors may have held elevated expectations or concerns regarding the future earnings impact of Humira's patent expiration.
• The slight drop in the stock price might also be linked to general market conditions or specific challenges within the pharmaceutical sector affecting investor sentiment.

15.04.2025 - ABBV Stock was down 5.0%

• The FDA fast-tracking AbbVie's new lung cancer therapy, Emrelis, may have sparked concerns among investors regarding the company's ability to meet high expectations, leading to profit-taking and a bearish trend.
• Unusual options activity indicating a bullish stance possibly initially boosted the stock, but the subsequent decline could suggest a shift in sentiment or profit realization by investors.
• The class action lawsuit against Cerevel Therapeutics Holdings, Inc., a company linked to AbbVie, likely created uncertainty and negative sentiment around AbbVie, contributing to the bearish movement.
• Representative Jared Moskowitz's significant purchase of AbbVie stock may have been viewed as a positive sign initially, but the overall market sentiment possibly overshadowed this, resulting in the bearish movement.

14.04.2025 - ABBV Stock was down 5.1%

• The bearish movement in AbbVie's stock price today could be attributed to profit-taking by investors after a recent increase in the stock value over the past month and year.
• The unusual options activity showing a bullish stance on AbbVie might indicate conflicting sentiments among investors, leading to increased volatility and potential sell-offs.
• The news of a Congressional report revealing a purchase of AbbVie stock by Representative Jared Moskowitz could have influenced market sentiment, but the overall impact on the stock price remains uncertain.
• The class action lawsuit notification against Cerevel Therapeutics Holdings, Inc. (ABBV) could have created negative sentiment around the pharmaceutical sector, impacting AbbVie's stock price negatively.

12.05.2025 - ABBV Stock was down 2.4%

• Despite positive FDA approval for Mavyret in pediatric patients with Hepatitis C and a significant purchase of AbbVie stock by Rep. Robert Bresnahan, the stock experienced a bearish movement.
• The market may have reacted negatively to concerns about AbbVie's ability to offset the sales drop post-U.S. patent loss of Humira, despite the expected growth from Skyrizi and Rinvoq.
• The overall market dip could have also contributed to AbbVie's bearish movement, as seen in the increase in stock price despite the market slip.
• Investors might be cautious about the company's future revenue streams and competitive positioning in the pharmaceutical industry, leading to the bearish trend in AbbVie's stock price.

01.09.2025 - ABBV Stock was up 6.3%

• The bullish trend in AbbVie's stock is linked to the company's announcement about seeking FDA approval for tavapadon, a potential treatment for Parkinson's disease. This development signifies advancement in the company's pipeline and hints at possible future revenue growth.
• While some investors showed bearish options activity, this viewpoint may be a short-term reaction, influenced by market fluctuations or individual strategies, rather than reflecting the overall optimistic outlook for AbbVie.
• AbbVie's shift beyond its successful drug Humira, with promising products like Skyrizi and Rinvoq, alongside its expansion into oncology and neuroscience fields, is likely instilling investor confidence and spurring the positive momentum in the stock.

01.09.2025 - ABBV Stock was up 5.5%

• AbbVie's upward movement is linked to its recent FDA filing for tavapadon, a potential treatment for Parkinson's disease. This development has instilled optimism among investors regarding the drug's potential success and its future impact on AbbVie's revenues.
• Options activity suggesting a bearish outlook on AbbVie may be due to profit-taking or hedging strategies among some investors. However, this activity has not significantly affected the overall market sentiment towards the stock.
• AbbVie's efforts to diversify its product portfolio beyond Humira, its blockbuster drug, with candidates like Skyrizi and Rinvoq in the development pipeline, have contributed to positive expectations for the company's growth prospects. This has further strengthened investor confidence in AbbVie's stock.

07.00.2026 - ABBV Stock was up 5.1%

• AbbVie's price target was increased to $240 by UBS, reflecting optimism about the company's performance.
• GuruFocus forecasts a possible downside for ABBV, indicating mixed perspectives on the stock.
• The positive outlook for AbbVie's growth potential and position in the pharmaceutical sector could be driving the bullish trend.
• The stock's upward momentum may be a response to the news of the raised price target, garnering favorable investor reactions.

08.00.2026 - ABBV Stock was down 5.3%

• AbbVie's stock decreased after lowering its Q4 and full-year 2025 guidance, receiving a downgrade from Wolfe Research, and refuting acquisition discussions with Revolution Medicines. These developments likely influenced the bearish movement.
• Xilio Therapeutics raised $35.8 million through warrant exercises and met a development milestone with AbbVie, providing positive news for Xilio amidst AbbVie's challenges, potentially shifting investor focus.
• AbbVie's denial regarding Revolution Medicines acquisition rumors, following a surge in Revolution's stock, contributed to market volatility and potentially impacted AbbVie's stock decline.
• Market sentiment towards pharmaceutical companies and their strategic decisions, exemplified by the varied news on AbbVie and Revolution Medicines, may have also influenced AbbVie's stock performance today.

31.06.2025 - ABBV Stock was down 0.2%

• AbbVie reported strong Q2 sales growth and raised its 2025 earnings outlook, but the stock faced downward pressure.
• Market reaction to the company missing EPS estimates despite exceeding sales expectations may be a factor.
• Concerns about the potential impact of Humira's future decline on revenue growth, despite growth in Skyrizi and Rinvoq, are looming.
• AbbVie's stock movement may have been influenced by the overall performance of the pharmaceutical industry, with upcoming earnings releases from other key players like MRK, AZN, BMY, and MRNA.